News & Events
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN (opens in a new tab)
– Clinical data, showing that 91.3% of subjects remained free of C. difficile infection recurrence at 8 weeks, support and extend previous Phase 3 study results – – SER-109 associated with rapid and steady improvement in HRQOL, an important patient-related outcome, compared with placebo through 8…
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (opens in a new tab)
– Company anticipates reporting initial SER-155 safety and pharmacological data from study Cohort 1 in the coming months – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 8, 2023– Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that enrollment in…
Genetic Analysis strengthens and future-proofs the organization (opens in a new tab)
OSLO, NORWAY, January 31, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA is strengthening and future-proofing the organization within business development, sales, and product development to be better positioned to harvest opportunities in the microbiome market. As diagn…
Genetic Analysis’ CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD (opens in a new tab)
OSLO, NORWAY, January 27, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA’s Chief Technology Officer Kari Furu was a finalist in the Lyfebulb 2022 Innovation Challenge in collaboration with Bristol Myers Squibb (“BMS”) to address unmet needs in Inflammatory Bowel Disease…
Genetic Analysis AS achieves Thai FDA License for GA-map[®] Dysbiosis Test in Thailand (opens in a new tab)
OSLO, NORWAY – 19 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) are happy to announce that Thailand Food and Drug Administration (“Thai FDA”) authority have granted GA license for the GA-map® Dysbiosis Test in Thailand. GA has, in cooperation with its distributor Hausen Bernstein Co. Ltd. (…
Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map[®] technology in India (opens in a new tab)
OSLO, NORWAY – 16 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a Tech Transfer Agreement with Microbiome Research Pvt. Ltd. (“MRPL”), a Mumbai based biotechnology company providing microbiome profiling services within the gut microbiome space in India. MRPL will launch a test s…
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jan. 13, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023 , the Compensation and Talent Committee of Seres’ board of directors granted inducement equity…
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress (opens in a new tab)
– Renowned investigator in microbial genomics to join Seres to advance Company’s efforts to develop novel microbiome therapeutics – – Following successful Data Safety Monitoring Board meeting in December for SER-155 Cohort 1, enrollment of Cohort 2 planned to begin in early 2023 – CAMBRIDGE,…
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jan. 4, 2023– Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 , at 8:15 a.m.…
Genetic Analysis AS enters an agreement with Hausen Bernstein Co. Ltd. to launch GA-map[®] technology in Thailand (opens in a new tab)
OSLO, NORWAY – November 30, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a tech transfer and distribution agreement with Hausen Bernstein Co. Ltd. (“HB”), a Bangkok-based fast-growing medical technology company with a diagnostic laboratory facility in Bangkok and a distribution busines…
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy (opens in a new tab)
– Event to highlight recurrent CDI market opportunity and SER-109 launch preparations – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 22, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the…
Genetic Analysis AS announces the outcome of the warrant exercise (opens in a new tab)
The post Genetic Analysis AS announces the outcome of the warrant exercise appeared first on Genetic Analysis.…
Last day of trading in warrants of series TO 1 is November 14, 2022 (opens in a new tab)
Oslo, Norway, November 10, 2022 – November 14, 2022, is the last day of trading in warrants of series TO 1, which were issued in connection with Genetic Analysis AS’s (“GA” or the “Company”) IPO of units in September/October 2021. The exercise period runs until November 16, 2022. Holders of warrants of series TO 1 are …
CORRECTION: Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis (opens in a new tab)
The press release published on November 2, 2022, at 08:00 CET, incorrectly stated November 16, 2022, as the last day of trading in warrants of series TO 1. The last day of trading in warrants of series TO 1 is November 14, 2022. The full press release, updated to reflect the correct date, follows below. Oslo, Norway, N…
Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map[®] in Europe (opens in a new tab)
OSLO, NORWAY – 7 November 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) today announces that GA has entered into an agreement with a leading non-disclosed global diagnostic company for the distribution of the GA-map® Dysbiosis Test in Europe. GA and the diagnostic partner are now in the launch phas…
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (opens in a new tab)
– Biologics License Application (BLA) for investigational microbiome therapeutic SER-109 for recurrent C. difficile infection (rCDI) accepted for Priority Review by U.S. Food and Drug Administration (FDA) – – PDUFA target action date is April 26, 2023 , with anticipated launch soon thereafter – –…
Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis (opens in a new tab)
The post Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis appeared first on Genetic Analysis.…
Correction: Interim report January – September 2022 (opens in a new tab)
Correction: In the press release sent at 08:00 this morning, the interim report was not included. It is now attached. Oslo, Norway, November 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2022. The interim report is available as an atta…
Interim report January – September 2022 (opens in a new tab)
The post Interim report January – September 2022 appeared first on Genetic Analysis.…
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 27, 2022– Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022 , at 8:30 a.m.…